Drug intelligence / Profile preview

VS-605

Development stage: Preclinical
Lead developer: Vidasym
Modality: Small Molecules

Overview

VS-605 is a small molecule drug candidate currently in preclinical development by Vidasym. It is being developed for the treatment of hyperphosphatemia associated with chronic kidney disease (CKD). The drug is designed to target phosphate, likely acting as a phosphate binder or an inhibitor of intestinal phosphate transport, to reduce elevated serum phosphorus levels in patients with impaired kidney function.

Targets

Pi (Inorganic phosphate)

Beyond the preview

Go deeper on VS-605.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VS-605.

Explore the full profile